Show simple item record

dc.contributor.authorRobert, C
dc.contributor.authorDummer, R
dc.contributor.authorGutzmer, R
dc.contributor.authorLorigan, Paul C
dc.contributor.authorKim, K
dc.contributor.authorNyakas, M
dc.contributor.authorArance, A
dc.contributor.authorLiszkay, G
dc.contributor.authorSchadendorf, D
dc.contributor.authorCantarini, M
dc.contributor.authorSpencer, S
dc.contributor.authorMiddleton, M
dc.date.accessioned2013-08-30T13:27:33Z
dc.date.available2013-08-30T13:27:33Z
dc.date.issued2013-07
dc.identifier.citationSelumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. 2013, 14 (8):733-40 Lancet Oncolen_GB
dc.identifier.issn1474-5488
dc.identifier.pmid23735514
dc.identifier.doi10.1016/S1470-2045(13)70237-7
dc.identifier.urihttp://hdl.handle.net/10541/300429
dc.description.abstractPatients with metastatic melanoma, 50% of whose tumours harbour a BRAF mutation, have a poor prognosis. Selumetinib, a MEK1/2 inhibitor, has shown antitumour activity in patients with BRAF-mutant melanoma and in preclinical models when combined with chemotherapy. This study was designed to look for a signal of improved efficacy by comparing the combination of selumetinib and dacarbazine with dacarbazine alone.
dc.language.isoenen
dc.rightsArchived with thanks to The lancet oncologyen_GB
dc.titleSelumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.en
dc.typeArticleen
dc.contributor.departmentInstitute Gustave Roussy, Paris, France. Electronic address: caroline.robert@igr.fr.en_GB
dc.identifier.journalLancet Oncologyen_GB
html.description.abstractPatients with metastatic melanoma, 50% of whose tumours harbour a BRAF mutation, have a poor prognosis. Selumetinib, a MEK1/2 inhibitor, has shown antitumour activity in patients with BRAF-mutant melanoma and in preclinical models when combined with chemotherapy. This study was designed to look for a signal of improved efficacy by comparing the combination of selumetinib and dacarbazine with dacarbazine alone.


Files in this item

This item appears in the following Collection(s)

Show simple item record